Payment overview · 2025
General Payments
$254.71
13 reported records · 5 companies
Healthcare provider profile · identity verified
Timothy J. Gray, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FOREST GROVE, OR · NPI 1003810441
Verified facts
What the public records show
CMS Open Payments records show Timothy J. Gray, D.O. received $254.71 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.24 | 29.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.73 | 22.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.47 | 21.4% | 3 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.18 | 17.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.09 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.71 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.47 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 115 |
| Lisinopril | Lisinopril | 340 | 102 |
| Gabapentin | Gabapentin | 320 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 84 |
| Losartan Potassium | Losartan Potassium | 305 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 237 | 73 |
| Omeprazole | Omeprazole | 211 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 56 |
| Metformin Hcl | Metformin Hcl | 188 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 43 |
| Eliquis | Apixaban | 157 | 34 |
| Furosemide | Furosemide | 146 | 46 |
| Potassium Chloride | Potassium Chloride | 128 | 40 |
| Simvastatin | Simvastatin | 118 | 33 |
| Trazodone Hcl | Trazodone Hcl | 114 | 33 |
| Baclofen | Baclofen | 110 | 31 |
| Sertraline Hcl | Sertraline Hcl | 107 | 30 |
| Metformin Hcl Er | Metformin Hcl | 106 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 42 |
| Mirtazapine | Mirtazapine | 96 | 27 |
| Allopurinol | Allopurinol | 95 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 18 |
| Glipizide Er | Glipizide | 93 | 25 |
| Montelukast Sodium | Montelukast Sodium | 92 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 25 |
| Alprazolam | Alprazolam | 90 | 14 |
| Prednisone | Prednisone | 90 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 88 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 24 |
| Buspirone Hcl | Buspirone Hcl | 86 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 86 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 17 |
| Ozempic | Semaglutide | 75 | 16 |
| Donepezil Hcl | Donepezil Hcl | 70 | 19 |
| Jardiance | Empagliflozin | 68 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 15 |
| Atenolol | Atenolol | 66 | 20 |
| Finasteride | Finasteride | 57 | 15 |
| Lovastatin | Lovastatin | 57 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Carvedilol | Carvedilol | 54 | 15 |
| Nystatin | Nystatin | 48 | 14 |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Tramadol Hcl | Tramadol Hcl | 46 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 13 |
| Ondansetron Odt | Ondansetron | 43 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Meloxicam | Meloxicam | 39 | 14 |
| Pregabalin | Pregabalin | 39 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Torsemide | Torsemide | 38 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 30 |
| Fluconazole | Fluconazole | 36 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 20 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | 12 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Lactulose | Lactulose | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 12 |
| Famotidine | Famotidine | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.71 · 13 records | ABBVIE INC. | AREXVY, BEXSERO, Korlym, Ozempic, PENMENVY, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error